Janssen and Legend Biotech Withdraw Planned ASH Abstract Comparing Carvykti to Anito-cel Due to Limited Public Data

LocalTime November 12, according to foreign media reports, Johnson & Johnson and Legend withdrew their plans for next month's American Society of Hematology.（ASH）Abstract presented at the annual meeting. It is reported that the abstract aims toComparisonCarvykti and Gilead/Arcellx's Upcoming BCMA CAR-T Therapyanito-cel。

Source: Fierce Pharma official website

Carvykti President Alan Bash stated during the Legend Q3 earnings conference,Due to limited data on anito-cel available through public channels, the company has negotiated the withdrawal of this abstract and looks forward to sharing the data in the future when the opportunity arises.

According toAccording to a report by Leerink Partners, Johnson & Johnson used a matched-adjusted indirect comparison for the analysis of the now-withdrawn study. (MAIC) Method: A comparison of the late-stage study of anito-cel with the results of Carvykti in the Cartitude-1 and early Cartitude-4 trials.

However, analysts believe that due toKey Prognostic Variables(Such as prior exposure to CD38 antibodies and patients being refractory to the last line of therapy)The overlap is limited and differences persist., unable to compare directly iMMagine-1（Anti-cel Key Phase II Clinical Trial）And Cartitude-1（Carvykti'sPhase Ib/II Clinical TrialResearch。

Leerink pointed out that the abstract claims patients are more likely to respond to Carvykti than anito-cel after adjusting for baseline prognostic factors. However, they disagree with this analytical approach and noted several flaws in the study, such as using complete response and very good partial response as efficacy comparison metrics instead of adopting the stricter minimal residual disease-negative criteria.

Anito-cel is Gilead Sciences &Arcellx CollaborationA BCMA CAR-T developed by Arcellx. Cross-trial results showed that the product demonstrated better safety in the later treatment of multiple myeloma, with efficacy comparable to...Carvykti is equivalent.

Bash stated that, in view of the competitive pressure brought by anito-cel in the later-line treatment space, Legend Biotech and Johnson & Johnson have been encouraging doctors to use Carvykti earlier in the disease course. At this stage, the patient's T cells are more suitable for CAR-T therapy modification and demonstrate better safety. Currently, about 60% of Carvykti prescriptions are for second- to fourth-line treatment patients. In Arcellx’s iMMagine-1 study, the median number of prior treatments received by enrolled patients was four lines.

Cover Source:Corporate logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb